Shares of Oncolytics Biotech Inc. (TSE:ONC – Get Free Report) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of C$14.90 and traded as low as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares.
Oncolytics Biotech Stock Performance
The firm has a 50 day moving average of C$14.90 and a 200 day moving average of C$14.90. The company has a quick ratio of 8.86, a current ratio of 2.88 and a debt-to-equity ratio of 14.58. The firm has a market cap of C$1.50 billion, a PE ratio of -40.27 and a beta of 0.80.
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.
Further Reading
- Five stocks we like better than Oncolytics Biotech
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
-american-depositary-shares-logo-1200x675.png){kind=logo}
